HK1048937A1 - 下调gdf-8活性的方法 - Google Patents
下调gdf-8活性的方法 Download PDFInfo
- Publication number
- HK1048937A1 HK1048937A1 HK03101114.6A HK03101114A HK1048937A1 HK 1048937 A1 HK1048937 A1 HK 1048937A1 HK 03101114 A HK03101114 A HK 03101114A HK 1048937 A1 HK1048937 A1 HK 1048937A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- gdf
- leu
- polypeptide
- pro
- glu
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Control Of Eletrric Generators (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA199901014 | 1999-07-20 | ||
| DKPA199901014 | 1999-07-20 | ||
| US14527599P | 1999-07-26 | 1999-07-26 | |
| US60/145,275 | 1999-07-26 | ||
| PCT/DK2000/000413 WO2001005820A2 (en) | 1999-07-20 | 2000-07-20 | Method for down-regulating gdf-8 activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1048937A1 true HK1048937A1 (zh) | 2003-04-25 |
Family
ID=26065065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK03101114.6A HK1048937A1 (zh) | 1999-07-20 | 2000-07-20 | 下调gdf-8活性的方法 |
Country Status (21)
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7393682B1 (en) * | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| US6369201B1 (en) | 1998-02-19 | 2002-04-09 | Metamorphix International, Inc. | Myostatin multimers |
| ES2330062T3 (es) * | 1998-05-06 | 2009-12-03 | Metamorphix, Inc. | Procedimientos para tratar la diabetes por inhibicion de gdf-8. |
| US7037501B2 (en) | 2001-01-04 | 2006-05-02 | Regents Of The University Of Minnesota | Myostatin immnoconjugate |
| TWI329129B (en) | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| JP2006501249A (ja) * | 2002-08-30 | 2006-01-12 | グラクソ グループ リミテッド | ワクチン |
| US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| AU2003301195B2 (en) * | 2002-12-20 | 2010-01-07 | Amgen Inc. | Binding agents which inhibit myostatin |
| WO2004108157A2 (en) | 2003-06-02 | 2004-12-16 | Wyeth | Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders |
| ITMI20071072A1 (it) | 2007-05-25 | 2008-11-26 | Lps Electronics S R L | Apparecchiatura per la rilevazione automatica dello stato di calore di una scrofa. |
| WO2005066204A2 (en) * | 2003-12-31 | 2005-07-21 | Schering-Plough Ltd. | Neutralizing epitope-based growth enhancing vaccine |
| JP4688483B2 (ja) | 2004-04-15 | 2011-05-25 | 株式会社テクノネットワーク四国 | フォリスタチン変異体ポリペプチド |
| CA2582940A1 (en) | 2004-09-30 | 2006-04-06 | Orico Limited | Myostatin isoform |
| US7888486B2 (en) | 2005-08-19 | 2011-02-15 | Wyeth Llc | Antagonist antibodies against GDF-8 |
| BRPI0715072A2 (pt) | 2006-08-03 | 2013-06-25 | Orico Ltd | antagonistas de miostatina |
| CN100450545C (zh) * | 2006-08-03 | 2009-01-14 | 中国医学科学院基础医学研究所 | 肌肉生长抑制素在制备抗肿瘤药物中的应用 |
| AU2008285289A1 (en) | 2007-08-03 | 2009-02-12 | Biomarin Iga Limited | Drug combinations for the treatment of Duchenne muscular dystrophy |
| GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
| KR100857861B1 (ko) * | 2007-10-15 | 2008-09-11 | 주식회사 바이오리더스 | Myo-2 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물 |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| US20140223592A1 (en) * | 2011-07-06 | 2014-08-07 | Pig Myostatin Gene Locus And Uses Thereof | Pig myostatin gene locus and uses thereof |
| SMT201800092T1 (it) | 2011-11-14 | 2018-03-08 | Regeneron Pharma | Composizioni e metodi per aumentare la massa muscolare e la forza muscolare antagonizzando specificamente gdf8 e/o activina a |
| MY177331A (en) | 2012-06-15 | 2020-09-12 | Pfizer | Improved antagonist antibodies against gdf-8 and uses therefor |
| EP4678239A3 (en) | 2012-08-01 | 2026-04-08 | Ikaika Therapeutics, Inc. | Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4) |
| HRP20201914T1 (hr) | 2013-05-06 | 2021-01-22 | Scholar Rock, Inc. | Sastavi i postupci za modulaciju faktora rasta |
| TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素a之抗體及其用途 |
| EP2960653A1 (en) * | 2014-06-24 | 2015-12-30 | Stichting Kwaliteitsgarantie Vleeskalversector | Diagnostic kit and method for the identification of the manipulation of muscle mass in a domestic animal |
| WO2016168613A1 (en) | 2015-04-15 | 2016-10-20 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
| IL276921B2 (en) | 2018-03-01 | 2025-12-01 | Regeneron Pharma | Methods for altering body composition |
| AU2019406214A1 (en) | 2018-12-21 | 2021-08-05 | Northwestern University | Use of annexins in preventing and treating muscle membrane injury |
| WO2020139977A1 (en) | 2018-12-26 | 2020-07-02 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
| US20240366760A1 (en) * | 2023-01-17 | 2024-11-07 | Regen BioPharma, Inc. | Activation of survivin-specific immune responses using dendritic cell derived exosomes |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6607884B1 (en) | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
| DK96493D0 (da) | 1993-08-26 | 1993-08-26 | Mouritsen Og Elsner Aps | Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden |
| CN1135181A (zh) | 1993-09-14 | 1996-11-06 | Cytel有限公司 | 使用泛dr结合肽改变免疫应答 |
| AUPO390396A0 (en) | 1996-11-29 | 1996-12-19 | Csl Limited | Novel promiscuous T helper cell epitopes |
| NZ337955A (en) | 1997-04-15 | 2000-09-29 | Ferring Farma Lab | Modified TNF-alpha and their use as vaccines |
| WO1999002667A1 (en) | 1997-07-14 | 1999-01-21 | University Of Liege | Mutations in the myostation gene cause double-muscling in mammals |
| EP1038016A2 (en) * | 1997-12-16 | 2000-09-27 | Valentis Inc. | Needle-free injection of formulated nucleic acid molecules |
| GB2333706A (en) | 1998-02-02 | 1999-08-04 | Merck & Co Inc | Method for increasing muscle mass in animals |
| US6369201B1 (en) * | 1998-02-19 | 2002-04-09 | Metamorphix International, Inc. | Myostatin multimers |
-
2000
- 2000-07-20 EE EEP200200025A patent/EE200200025A/xx unknown
- 2000-07-20 HU HU0201861A patent/HUP0201861A3/hu unknown
- 2000-07-20 MX MXPA01013232A patent/MXPA01013232A/es active IP Right Grant
- 2000-07-20 HR HR20010900A patent/HRP20010900A2/hr not_active Application Discontinuation
- 2000-07-20 WO PCT/DK2000/000413 patent/WO2001005820A2/en not_active Ceased
- 2000-07-20 TR TR2004/00621T patent/TR200400621T2/xx unknown
- 2000-07-20 AU AU59675/00A patent/AU778470B2/en not_active Ceased
- 2000-07-20 US US09/620,586 patent/US7056512B1/en not_active Expired - Fee Related
- 2000-07-20 TR TR2002/00133T patent/TR200200133T2/xx unknown
- 2000-07-20 CA CA002379852A patent/CA2379852A1/en not_active Abandoned
- 2000-07-20 PL PL00353855A patent/PL353855A1/xx unknown
- 2000-07-20 HK HK03101114.6A patent/HK1048937A1/zh unknown
- 2000-07-20 JP JP2001511477A patent/JP2003506325A/ja active Pending
- 2000-07-20 EA EA200200182A patent/EA005248B1/ru not_active IP Right Cessation
- 2000-07-20 SK SK72-2002A patent/SK722002A3/sk unknown
- 2000-07-20 CN CN00810614A patent/CN1384757A/zh active Pending
- 2000-07-20 NZ NZ517058A patent/NZ517058A/en unknown
- 2000-07-20 IL IL14684500A patent/IL146845A0/xx unknown
- 2000-07-20 EP EP00945671A patent/EP1200119A2/en not_active Withdrawn
- 2000-07-20 US US10/031,342 patent/US7070784B1/en not_active Expired - Fee Related
- 2000-07-20 KR KR1020027000866A patent/KR100750695B1/ko not_active Expired - Fee Related
-
2001
- 2001-11-30 ZA ZA200109901A patent/ZA200109901B/xx unknown
- 2001-12-19 NO NO20016252A patent/NO20016252L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200109901B (en) | 2003-05-28 |
| KR20020026544A (ko) | 2002-04-10 |
| KR100750695B1 (ko) | 2007-08-22 |
| EP1200119A2 (en) | 2002-05-02 |
| MXPA01013232A (es) | 2005-05-24 |
| AU778470B2 (en) | 2004-12-09 |
| AU5967500A (en) | 2001-02-05 |
| NZ517058A (en) | 2004-04-30 |
| HUP0201861A2 (en) | 2002-09-28 |
| SK722002A3 (en) | 2003-02-04 |
| WO2001005820A3 (en) | 2001-07-19 |
| NO20016252L (no) | 2002-03-15 |
| HUP0201861A3 (en) | 2004-07-28 |
| JP2003506325A (ja) | 2003-02-18 |
| US7070784B1 (en) | 2006-07-04 |
| TR200400621T2 (tr) | 2004-08-23 |
| PL353855A1 (en) | 2003-12-01 |
| IL146845A0 (en) | 2002-07-25 |
| NO20016252D0 (no) | 2001-12-19 |
| US7056512B1 (en) | 2006-06-06 |
| TR200200133T2 (tr) | 2002-05-21 |
| CA2379852A1 (en) | 2001-01-25 |
| HRP20010900A2 (en) | 2003-08-31 |
| WO2001005820A2 (en) | 2001-01-25 |
| CN1384757A (zh) | 2002-12-11 |
| EA005248B1 (ru) | 2004-12-30 |
| EE200200025A (et) | 2003-04-15 |
| EA200200182A1 (ru) | 2002-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1384757A (zh) | 下调gdf-8活性的方法 | |
| CN1279971C (zh) | 下调淀粉状蛋白的新方法 | |
| HK1040261A1 (zh) | 负调节osteoprotegerin配体活性的方法 | |
| CN1178955C (zh) | 经修饰的TNFα分子和编码该TNFα分子的DNA以及含有该TNFα分子和该DNA的疫苗 | |
| CN1308037C (zh) | 增强蛋白和肽抗原免疫原性的Fc融合蛋白 | |
| CN1249085C (zh) | 诱导对β淀粉状蛋白和淀粉状蛋白沉积物的免疫反应、与β淀粉状蛋白同源的免疫源性但非淀粉状蛋白源性合成肽 | |
| CN1568329A (zh) | 一种用于预防和治疗阿尔兹海默氏病的具有免疫原性的肽组合物 | |
| CN1171814A (zh) | 多核苷酸结核病疫苗 | |
| CN1538854A (zh) | 作为佐剂的霍乱全毒素的突变体形式 | |
| CN1541111A (zh) | 作为佐剂的霍乱全毒素的突变形式 | |
| CN1194000A (zh) | 增强保护性免疫应答的方法 | |
| CN1549726A (zh) | 先天性免疫系统指导的疫苗 | |
| CN1543504A (zh) | 疫苗 | |
| CN1355846A (zh) | 用于下调节白细胞介素5活性的方法 | |
| CN1871025A (zh) | 基于印记位点调节物兄弟(boris)的预防性癌症疫苗 | |
| CN1615316A (zh) | 多聚体蛋白质的新免疫原性模拟物 | |
| CN1741818A (zh) | 线虫多肽佐剂 | |
| CN1639569A (zh) | 诱导免疫应答的方法和组合物 | |
| CN1956727A (zh) | 诱导抗金黄色葡萄球菌的保护性免疫应答的多肽 | |
| CN1656116A (zh) | 包含hpv-16病毒的突变e7蛋白的非免疫抑制免疫原性组合物或疫苗组合物 | |
| CN1191090C (zh) | 与抗原相结合的肠细菌OmpA蛋白用于产生抗病毒、抗寄生虫、或抗肿瘤的细胞毒性应答的用途 | |
| CN1960744A (zh) | 肽IL1β和TNFα以及应用其治疗的方法 | |
| CN1191091C (zh) | 新型免疫疾病预防剂/治疗剂 | |
| CN1893970A (zh) | β-淀粉样蛋白-类似物-T-细胞表位疫苗 | |
| CN1653084A (zh) | 酶活性减少的非典型流感嗜血杆菌的p4蛋白突变体 |